Guangzhou Sceptre Pharmaceutical Technology

Guangzhou Sceptre Pharmaceutical Technology is a clinical-stage biotechnology company based in China that specializes in the development of innovative therapies for central nervous system (CNS) disorders. The company's primary focus is on neuroprotection and the preservation of the neurovascular unit to treat conditions such as acute ischemic stroke and neurodegenerative diseases. Its lead candidate, SP-8203 (otaplimastat), is a first-in-class small molecule inhibitor of matrix metalloproteinases designed to reduce brain injury and hemorrhagic transformation following stroke. Sceptre's pipeline also includes early-stage programs targeting Alzheimer's disease and other neurological conditions. The company aims to address significant unmet medical needs in the global aging population through its specialized neurobiology research platform.